Key insights
- Eli Lilly will present positive hematology data, including Phase 3 results for Jaypirca and early data from its acquisitions of Ajax Therapeutics and Kelonia Therapeutics, at the EHA meeting. This highlights continued pipeline strength and potential future growth drivers, reinforcing positive sentiment around the company's expanding oncology and hematology franchises.
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today it will present data from its hematology portfolio at the European Hematology Association Annual Meeting, scheduled for June 11-14 in Stockholm, Sweden, according to a press release statement. The pharmaceutical giant, with a market capitalization of $954.9 billion, has delivered impressive revenue growth of 47% over the last twelve months as of Q1 2026.
The company will present results from the Phase 3 BRUIN CLL-322 study of Jaypirca (pirtobrutinib) in a late-breaking oral presentation on Sunday. The study evaluated a time-limited regimen of pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Lilly previously announced the study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival. According to InvestingPro analysis, 18 analysts have revised their earnings upwards for the upcoming period, reflecting confidence in the company’s expanding hematology pipeline. The platform offers comprehensive Pro Research Reports on Lilly and 1,400+ other US equities.
Ajax Therapeutics, which Lilly has agreed to acquire, will present initial clinical results from the Phase 1 AJX-101 trial evaluating AJ1-11095, a type II JAK2 inhibitor, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. The presentation is scheduled for Saturday.
Kelonia Therapeutics, also subject to a proposed acquisition by Lilly, will present additional data from the Phase 1 inMMyCAR study evaluating KLN-1010 in patients with relapsed or refractory multiple myeloma on Thursday.
The Ajax Therapeutics acquisition is expected to close in June 2026, while the Kelonia Therapeutics transaction is expected to close in the second half of 2026, pending regulatory approvals and customary closing conditions.
Jaypirca is currently approved for treating adult patients with relapsed or refractory CLL/SLL who have previously been treated with a covalent BTK inhibitor, and for adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy.
In other recent news, Eli Lilly and Company has announced agreements to acquire three vaccine development companies—Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc.—for a combined potential value of up to $3.83 billion. This acquisition aims to enhance Eli Lilly’s research and development in infectious diseases. Additionally, Eli Lilly will present phase 3 clinical trial results for Foundayo and retatrutide at the American Diabetes Association’s Scientific Sessions. The ACHIEVE-3 study highlighted Foundayo’s superior A1C reduction and significant weight loss in type 2 diabetes patients compared to oral semaglutide. Meanwhile, Eli Lilly’s obesity medicine Zepbound will be added to CVS Caremark’s preferred drug list, with coverage beginning June 1. This move ensures that all three of the nation’s largest pharmacy benefit managers will cover Lilly’s full obesity medicine portfolio.
Novartis has reported promising early data from its experimental actinium-based drug for prostate cancer. In a study involving 101 patients, 52.5% of those previously treated with Pluvicto experienced a significant reduction in prostate-specific antigen levels. The response was even more pronounced in patients who had not received prior treatment. In France, the government will begin reimbursing the cost of weight-loss drugs for severely obese patients from mid-June, including Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro. This makes France the first EU country to offer such reimbursement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates LLY alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if LLY is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?